FY2027 EPS Estimate for DBV Technologies Lowered by Analyst

DBV Technologies S.A. (NASDAQ:DBVT) – Investment analysts at HC Wainwright lowered their FY2027 earnings estimates for DBV Technologies in a research note issued on Friday, July 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($1.45) for the year, down from their prior estimate of ($1.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2028 earnings at $1.15 EPS, FY2029 earnings at $3.85 EPS and FY2030 earnings at $6.65 EPS.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The firm had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.

A number of other research firms also recently commented on DBVT. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp raised their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Weiss Ratings lowered shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Finally, Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, DBV Technologies currently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Price Performance

NASDAQ DBVT opened at $14.22 on Tuesday. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18. The company has a market capitalization of $841.97 million, a P/E ratio of -4.05 and a beta of -0.95. The business has a 50 day moving average price of $16.91 and a 200 day moving average price of $19.41.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC purchased a new position in DBV Technologies during the first quarter worth $20,146,000. Vivo Capital LLC raised its holdings in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of DBV Technologies in the first quarter valued at $21,159,000. Royal Bank of Canada lifted its position in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after acquiring an additional 2,928 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies during the first quarter valued at $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.